8N10 Stock Chart & Stats
€0.12
<€0.01(4.55%)
―
--
Day’s Range― - ―
52-Week Range€0.05 - €0.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€10.02M
Enterprise Value€77.44
Total Cash (Recent Filing)€3.23M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta4.70
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.61
Shares Outstanding82,188,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)72.03
Price to Sales (P/S)0.00
P/FCF Ratio-23.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)€127.64K
Bulls Say, Bears Say
Bulls Say
Debt-free Capital StructureHaving no financial debt reduces insolvency and refinancing pressure, preserving flexibility while Biosergen advances its development program. This structure avoids mandatory interest and principal payments, although the company still needs funding because operations remain loss-making.
Improved Losses Versus 2025The reduction in net loss versus 2025 indicates some improvement in reported earnings performance, even though profitability remains distant. If sustained, lower losses could moderate cash requirements and extend operating capacity while the company develops its lead therapy.
Focused Antifungal Development AssetBiosergen has a clearly defined therapeutic focus and a lead asset rather than a diffuse portfolio description. Successful development of BSG005 could establish a commercial product opportunity, giving the company a potentially meaningful path beyond its current R&D-stage status.
Bears Say
No Meaningful Revenue BaseThe absence of a meaningful revenue base shows that Biosergen has not yet demonstrated commercial traction or operating leverage. Continued dependence on development progress leaves future income uncertain and means fixed research spending cannot currently be supported by product sales.
Persistent Negative Cash FlowSustained negative operating and free cash flow means the business consumes cash to continue operating rather than generating internal funding. This creates ongoing reliance on external financing and can constrain development plans if capital becomes more difficult or costly to obtain.
Sharp Equity CompressionThe sharp decline in equity signals substantial cumulative financial pressure and may reflect burn and/or dilution effects. A much smaller equity base reduces the company’s financial cushion, increases sensitivity to further losses, and can limit flexibility in funding its pipeline.
8N10 FAQ
What was Biosergen AB’s price range in the past 12 months?
Biosergen AB lowest stock price was €0.05 and its highest was €0.55 in the past 12 months.
What is Biosergen AB’s market cap?
Biosergen AB’s market cap is €10.02M.
When is Biosergen AB’s upcoming earnings report date?
Biosergen AB’s upcoming earnings report date is Nov 18, 2026 which is in 71 days.
How were Biosergen AB’s earnings last quarter?
Biosergen AB released its earnings results on Feb 10, 2026. The company reported -€0.052 earnings per share for the quarter.
Is Biosergen AB overvalued?
According to Wall Street analysts Biosergen AB’s price is currently Undervalued.
Does Biosergen AB pay dividends?
Biosergen AB does not currently pay dividends.
What is Biosergen AB’s EPS estimate?
Biosergen AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosergen AB have?
Biosergen AB has 82,188,120 shares outstanding.
What happened to Biosergen AB’s price movement after its last earnings report?
Biosergen AB reported an EPS of -€0.052 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biosergen AB?
Currently, no hedge funds are holding shares in DE:8N10
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biosergen AB
Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.
Technical Analysis
BioInvent International AB
―
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―